Publications by authors named "Xavier Bourge"

Claim this Profile
T
The impact of carbapenem-resistant infections in intensive care units: focus on non-fermenting gram-negative bacilli and survival analysis.
Juliette Dessemon, Charles-Hervé Vacheron, Anne Savey, Anaïs Machut, Arnaud Friggeri, Xavier Bourge

Antimicrob Resist Infect Control· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antimicrobial activity of new anti-Pseudomonas beta-lactam-beta-lactamase inhibitors against Pseudomonas aeruginosa respiratory isolates recovered during the study for Monitoring Antimicrobial Resistance Trends (SMART) program in France (2016-2022).
Charlie Zins, Hélène Pailhoriès, Rachel Chenouard, Stéphane Corvec, Sandrine Dahyot, Xavier Bourge

Infect Dis Now· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and Economic Burden Associated With Anti-Cytomegalovirus (CMV) Prophylaxis Therapies in Adult Kidney Transplant Recipients (LECOCYT): An Observational Study.
Nassim Kamar, Hannah Kaminski, Christophe Masset, Claire Castagné, Guilhem Tournaire, Xavier Bourge

Transpl Int· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Ceftolozane/Tazobactam for the Treatment of Adults With Cystic Fibrosis: Results From a French Prospective Cohort Study.
Pierre-Régis Burgel, Xavier Bourge, Carole Mackosso, Francois Parquin

Open Forum Infect Dis· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Ceftolozane/Tazobactam for the Treatment of Complicated Infections in Hospital Settings-A French Real-world Study.
Jean-François Timsit, Joy Mootien, Brune Akrich, Xavier Bourge, Isabelle Brassac

Open Forum Infect Dis· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis